[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:gaucher-s-disease-type-i":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Gaucher's disease, type I",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05487599","A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-03T03:24:20.303158Z","2026-05-05T02:43:28.299365Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07223944","A Gaucher Disease Gene Therapy Trial With FLT201",[19],"Phase 3","2026-08-26T02:18:48.678868Z","2026-05-05T02:43:26.900074Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT02437396","Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease",[],"2026-08-26T02:17:39.048487Z","2026-05-13T02:55:06.095239Z",[],[]]